ATRA : Insider Transactions for Atara Biotherapeutics, Inc. | J3SG

Sign in:	Email	Password save:

		Company Reports
Find Symbol

Recent: Companies Filers Institutions

Membership is free, please Sign Up.

My Recent Searches

Help

Roster

Institutions

Add To Portfolo/Alerts

Get Insiders for :

Atara Biotherapeutics, Inc. (ATRA)

$0.39 0.00 (0.00%) as of 4:30 Tue 6/18

Download

Exchange:

N/A

Security Type:

N/A

Shares Out:

108,674,000

Market Cap:

42.88(M)

Last Volume:

0

Avg Vol:

0

52 Week Range:

$0.2298 - $2.31

Level I Sector:

N/A

Level II Sector:

N/A

Level III Sector:

N/A

Member Indexes:

Rankings:

Insider 3 Months : -

Insider 6 Months : -

Insider 3/6 Months : -

Guru Rank Number : 707

Guru Rank Value : 1.9

Guru Occurances : 1


6 Months 1 Year 2 Year

Company Profile Atara Biotherapeutics is engaged in T-cell immunotherapy, using its allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for patients with diseases, including tumors, hematologic cancers and autoimmune disease. Co.'s platform utilizes the biology of EBV T cells and has the capability to treat a range of EBV-driven diseases or other diseases through incorporation of engineered chimeric antigen receptors or T-cell receptors. Co.'s T-cell immunotherapy program, tab-cel® (tabelecleucel), is partnered with Pierre Fabre Medicament and is in Phase 3 development for patients with EBV-driven post-transplant lymphoproliferative disease.

D/I:

D is for direct shares.
I is for indirect shares.

D/I refers to the Direct or Indirect shares traded vs. held.

Forms:

A Form 4 is a form filed by an insider to indicate a change in ownership.

A Form 3 is a form filed by an insider to indicate an initial ownership of a security.

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.

Actions:

B	Buy
S	Sell
OE	Option Exercised
A	Acquired
D	Disposed
AB	Automatic Buy
AS	Automatic Sell
IO	Initial Ownership

Download:

Download only Transactions Forms. (Default)

Download only Summary Infomation.

Download both Transactions and Summary Data

Summary (Direct Transactions Only)	3 Months	6 Months	12 Months	24 Months
Total Shares Bought	0	0	816,825	816,825
Total Buy Value	$0	$0	$194,885	$194,885
Total People Bought	0	0	3	3
Total Buy Transactions	0	0	4	4
Total Shares Sold	211,204	267,396	419,842	591,605
Total Sell Value	$130,313	$170,773	$340,560	$980,941
Total People Sold	5	5	6	9
Total Sell Transactions	5	10	23	41
End Date	2024-03-28	2023-12-26	2023-06-27	2022-06-27

Adjust Filter Settings

Records found: 736

Page 21 of 30

Filer's Name

Relation Title

Off-Dir-10%

D/I

Rank

3m +/-

Form

Gallagher Carol Giltner

Director

– • –

2017-02-15

4

OE

$0.00

$0

D/D

2,365

103,375

-

EVP & Chief Financial Officer

• – –

2017-02-15

4

OE

$0.00

$0

D/D

10,501

159,827

-

EVP & Chief Strategy Officer

• – –

2017-02-15

4

OE

$0.00

$0

D/D

13,762

276,300

-

Director

– • –

2017-02-15

4

OE

$0.00

$0

D/D

1,603

20,696

-

Clark Mitchall G.

EVP & Chief R & QA Officer

• – –

2017-02-15

4

OE

$0.00

$0

D/D

7,211

152,720

-

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2017-02-15

4

AS

$15.49

$117,786

D/D

(7,604)

392,855

-

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2017-02-15

4

OE

$0.00

$0

D/D

829

400,459

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-02-15

4

AS

$15.54

$37,296

I/I

(2,400)

351,378

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-02-15

4

OE

$0.00

$0

D/D

5,907

725,951

-

EVP & Chief Strategy Officer

• – –

2017-02-14

4

AS

$15.22

$106,540

D/D

(7,000)

262,538

-

EVP & Chief Strategy Officer

• – –

2017-02-10

4

AS

$15.42

$97,029

D/D

(6,274)

269,538

-

Turner Heather D

EVP, General Counsel & Sec.

• – –

2017-02-09

4

AS

$15.70

$192,067

D/D

(12,215)

86,142

-

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2017-02-09

4

AS

$15.46

$216,054

D/D

(13,975)

399,630

-

EVP & Chief Financial Officer

• – –

2017-02-06

4

A

$0.00

$0

D/D

49,500

149,326

-

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2017-02-06

4

A

$0.00

$0

D/D

49,500

413,605

-

EVP & Chief Strategy Officer

• – –

2017-02-06

4

A

$0.00

$0

D/D

45,000

275,812

-

Turner Heather D

EVP, General Counsel & Sec.

• – –

2017-02-06

4

A

$0.00

$0

D/D

49,500

98,357

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-02-03

4

AS

$13.87

$33,288

I/I

(2,400)

353,778

-

Ciechanover Isaac E.

Chief Executive Officer

• • –

2017-02-02

4

AS

$13.45

$32,280

I/I

(2,400)

356,178

-

Haqq Christopher

EVP, R&D & Chief Scientific Of

• – –

2017-01-17

4

AS

$14.27

$85,620

D/D

(6,000)

364,105

-

Director

– • –

2017-01-03

4

A

$0.00

$0

D/D

2,000

7,500

-

Director

– • –

2017-01-03

4

A

$0.00

$0

D/D

2,000

2,000

-

Gallagher Carol Giltner

Director

– • –

2017-01-03

4

A

$0.00

$0

D/D

2,000

101,010

-

Seidenberg Beth C

Director

– • –

2017-01-03

4

A

$0.00

$0

D/D

2,000

8,689

-

Heiden William K

Director

– • –

2017-01-03

4

A

$0.00

$0

D/D

2,000

2,000

-

736 Records found	Previous 20 21 22 23 24 25 26 27 28 29 Next	Page 21 of 30

	Transaction Code Key:				Ownership Code Key
	B	- Buy	AB	- Automatic Buy	D	- Direct Ownership
	S	- Sell	AS	- Automatic Sell	I	- Indirect Ownership
	OE	- Options Exercised	A	- Acquired
	IO	- Initital Ownership	D	- Disposed

Copyright © 2024 j3sg.com | Disclaimer & Terms of use Products & Service About Us Contact Us

Summary:

Chart:

3m +/-:

This represents the company's 3 month price change. The initial price is based on the closing price of the stock on the day the transaction took place. Purchases & sales are viewed as long & short positions respectively.